Provided by Tiger Trade Technology Pte. Ltd.

Spero Therapeutics Inc.

1.19
+0.03002.59%
Post-market: 1.15-0.0400-3.36%19:58 EDT
Volume:11.77M
Turnover:13.47M
Market Cap:68.89M
PE:4.56
High:1.23
Open:1.14
Low:1.08
Close:1.16
52wk High:3.08
52wk Low:1.08
Shares:57.89M
Float Shares:45.59M
Volume Ratio:5.41
T/O Rate:25.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.2608
EPS(LYR):0.1500
ROE:35.12%
ROA:12.96%
PB:1.30
PE(LYR):7.93

Loading ...

Innovent Biologics Shares Surge on Spero Deal That Could be Worth $1.1 Bln

Dow Jones
·
Jul 15

Sector Update: Healthcare Stocks Mixed Premarket Tuesday

MT Newswires Live
·
Jul 14

Spero Licenses Innovent's Experimental Immune Disease Drug for up to $1.1 Billion

Reuters
·
Jul 14

Spero Therapeutics secures $105M non-dilutive financing to develop SP001

TIPRANKS
·
Jul 14

Spero Therapeutics Secures $105 Million Royalty-backed Financing from Healthcare Royalty (KKR)

Reuters
·
Jul 14

Spero Therapeutics - Updates Cash Runway Guidance into Second Half of 2029

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Hcrx to Provide $105 Mln Payment at Closing for Rights to Utebzi Payments from GSK

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Proceeds to Support Advancement of Lead Immunology Drug Candidate SP001

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Retain 35% of Subsequent GSK Payments Related to Utebzi Sales After Repayment

THOMSON REUTERS
·
Jul 14

Spero Therapeutics Announces $105 Million Non-recourse Non-dilutive Financing Backed by a Portion of Utebzi Milestones & Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Hcrx to Receive Quarterly Principal and Interest Payments Derived from the GSK Payments Due to Spero Until Loan Repaid

THOMSON REUTERS
·
Jul 14

Innovent Biologics Licenses Anti-cd40l Antibody Ibi355 to Spero in Deal Worth About USD 1.1 Billion

Reuters
·
Jul 14

Spero Therapeutics - Innovent to Receive Payments Totaling About $1.1 Bln Plus Tiered Royalties

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - Innovent to Initiate Phase 2 Trial for Sjögren’s Disease in China by Early 2027

THOMSON REUTERS
·
Jul 14

Spero Therapeutics - to Initiate Phase 2 Trial for SP001 in Igg4-rd in Q2 2027

THOMSON REUTERS
·
Jul 14

Innovent Biologics - Spero Receives Exclusive Global Rights to Ibi355 Excluding Greater China

THOMSON REUTERS
·
Jul 14

Innovent Biologics and Spero Therapeutics Announce Exclusive License for Ibi355 (sp001), a Phase 2-ready Third-generation Anti-cd40l Antibody

THOMSON REUTERS
·
Jul 14

Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors

GlobeNewswire
·
Jul 08

Spero Therapeutics Shareholders Approved Increase in Authorized Common Shares to 240 Million

Reuters
·
Jun 26

Spero Therapeutics says FDA approves Utebzi oral antibiotic for complicated UTIs in adults

Reuters
·
Jun 23